2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3413 Real-world multicenter outcomes of cladribine with low-dose cytarabine and venetoclax in intensive chemotherapy ineligible patients with newly diagnosed and relapsed/refractory acute myeloid leukemia

Himachandana Atluri, MD, Sarah Marini, MD2, Rafael Madero-Marroquin, MD3, Anand Ashwin Patel, MD4, Ashley D Hadjis, MD5, Curtis Lachowiez, MD6, Alexander Coltoff, MD7, Nepheli Raptis, MD8, Jessica Lewis-Gonzalez, PharmD, BCOP9, Charles Foucar, MD10, Talha Badar, MD11, Mahesh Kumar, MD12, Jessica Kaplan Altman, MD13, Yasmin Abaza, MD14
1 Northwestern University, Chicago, Illinois, United States
2 Northwestern University, Chicago, Illinois, United States
3 University of Chicago, Chicago, Illinois, United States
4 University of Chicago, Chicago, Illinois, United States
5 Oregon Health and Sciences University, Portland, Oregon, United States
6 Oregan Health and Sciences University, Portland, Oregon, United States
7 Medical University of South Carolina, Charleston, South Carolina, United States
8 Northwestern University, Chicago, United States
9 University of New Mexico, Albuquerque, New Mexico, United States
10 University of New Mexico, Albuquerque, New Mexico, United States
11 Mayo Clinic, Jacksoville, Florida, United States
12 Mayo Clinic, Jacksonville, Florida, United States
13 Northwestern University, Chicago, Illinois, United States
14 Northwestern University, Chicago, Illinois, United States

Background

Venetoclax (VEN) combined with hypomethylating agents (HMA) or low-dose cytarabine (LDAC) are established as the standard of care for adults with newly diagnosed (ND) acute myeloid leukemia (AML) that are ineligible for intensive chemotherapy. Recent studies evaluating the addition of Cladribine (Clad) to LDAC + VEN demonstrated complete remission or complete remission with incomplete hematologic recovery (CR/CRi) rates of 86% with up to 84%  patients attaining MRD negativity in some studies. We aim to analyze real-world outcomes using this regimen in patients with ND and relapsed/refractory (R/R) AML.

Methods

This multicenter, retrospective study to evaluated baseline characteristics and clinical outcomes following Clad/LDAC + VEN in patients with ND or R/R AML. Responses were assessed using ELN22 criteria. Overall response rate (ORR) includes patients achieving a complete response (CR), complete response with incomplete count recovery (CRi), complete response with partial hematologic recovery (CRh), partial response (PR), and morphologic leukemia free state (MLFS). Time-to-event analysis was performed using the Kaplan-Meier method and assessed using the log-rank test. Overall survival (OS) was calculated from start of therapy to date of death or last follow up, whichever occurred first.

Results

A total of 103 patients (49 ND, 54 R/R) were treated from between October 2021 to December 2025. Median age at treatment initiation  was 69 years (42-86) and 70 years (46-84) for the ND and R/R cohorts, respectively.  

In the ND cohort, 10% (n=5) had favorable, 10% (n=5) intermediate, and 80% (n=39) had adverse risk disease using ELN 2022 criteria. By ELN 2024, 41% (n=20) had favorable, 35% (n=17) intermediate, and 24% (n=12) adverse risk disease. K/NRAS andTP53 mutations were found in 30% (n=15) and 18% (n=9) of patients, respectively. Fifty-nine percent (n=29) of patients had secondary (n=13), secondary treated (n=14), and therapy related AML (n=2).

The ORR was 69% (n=38); 42% achieved CR (n=21), 18% (n=9) achieved CRi,  8% (n=4) attained a MLFS, and 8% (n=4) achieved a PR. Median time to ANC recovery ≥ 0.5 x 103/µL was 28 days (range 13-75) and median time to platelet recovery ≥ 50 x 103/µLwas 24.5 days (range 14 – 291) in responding patients. After a median follow up of 16.5 months, median OS was 10.8 months (95% CI 9.08 – NA); median OS was NR (95% CI 5.79 – NA) in patients with de novo AML and 17.63 mos (95% CI 12.83 – NA) in pts with sAML (n=13) . Median OS in pts harboring K/NRAS (n=15) and TP53 mutations (n=9) were 10.0 mos (95% CI 3.91 – NA) and 3.91 months (95% CI 2.27 – NA), respectively. Using ELN 2024, median OS for patients with favorable, intermediate, and adverse risk disease were 21.68 mos (95% CI 10.69 – NA), 17.63 (95% CI 10 - NA) and 5.03 months (95% CI 3.88 – NA), respectively. Fourteen patients (26%) underwent allogeneic stem cell transplant (alloSCT) in CR1. A total of 8 patients (15%) relapsed, 2 relapsed after alloSCT. 30- and 60-day mortality was 4% (n=2) and 8% (n=4), respectively.

 In the R/R cohort (n=54), the ORR was 46% (n=25) of which 10 (19%) achieved CR, 5 (9%) CRh, 4 (7%) CRi, 4 (7%) achieved a PR, and 4 (7%) achieved MLFS. Median lines of prior therapy were 1 (range 1-11). Eighty-nine percent of patients (n=48) received prior VEN and 15% (n=8) had prior alloSCT. Five patients (9%) underwent alloSCT after attaining second complete remission. With a median follow up of 13.8 months, the median OS for the R/R cohort was 4.94 months (95% CI 4.08 – 7.17). Among K/NRAS and TP53 mutated pts (n=12), median OS was 3.22 months, and  4.57 months, respectively.

Summary/Conclusion

Clad/LDAC + VEN is an effective treatment option for patients with  ND and R/R AML. Despite the high-risk patient population included, Clad/LDAC + Ven was associated with high CR/CRi rates and encouraging OS in patients with ND-AML making it an attractive treatment option in the frontline setting. Larger studies comparing Clad/LDAC + Ven to HMA+VEN are warranted.

Himachandana Atluri, MD: No relevant conflicts of interest to declare.